• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 26, 2014

View Archived Issues

'CAR' lots: $50M class A joins Conkwest, Sorrento in allogeneic cancer bid

Another vote for cancer immunotherapy came in the form of $50 million in class A stock-sale money for Conkwest Inc., including $48 million from Nantworks Inc. founder and well-known biotech entrepreneur Patrick Soon-Shiong plus $2 million from Sorrento Therapeutics Inc. Read More

Innovation the order of the day as tissue manipulation takes the stage

WASHINGTON – A substantial portion of basic medical research goes someplace to expire without ever seeing clinical daylight, but the last day of TERMIS 2014, sponsored by the Tissue Engineering and Regenerative Medicine International Society (TERMIS) earlier this month highlighted some ingenious technological developments, some of which will surely find a place in routine use. Read More

Will pay-for-delay settlements become a trend of the past?

With courts cracking down on pay-for-delay (PFD) settlements between brand drugmakers and generic competitors, the impact of those settlements may be on the decline. Read More

First partial success for prion disease vaccine reported

Scientists have developed a vaccine that partially protected deer from developing chronic wasting disease (CWD), a prion disease that is the deer equivalent of Creutzfeldt-Jakob disease and other prion diseases, as well as Scrapie in sheep, and bovine spongiform encephalopathy (BSE or 'mad cow disease') in cattle. Read More

Holiday notice

BioWorld's offices were closed Thursday, Dec. 25, in observance of the Christmas Day holiday in the U.S. No issues were published those days. Read More

Other news to note

Amarantus Bioscience Holdings Inc., of San Francisco, said the FDA granted the company's investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) orphan drug designation for the treatment of retinitis pigmentosa (RP), a group of inherited diseases causing retinal degeneration often leading to blindness. Read More

Pharma: Other news to note

Actavis plc, of Dublin, received a complete response letter (CRL) from the FDA for its new drug application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension. Data submitted to the FDA in support of approval of this NDA included a single phase III randomized, controlled trial of approximately 4,100 patients. Read More

Financings

Juno Therapeutics Inc., of Seattle, reported the closing of its initial public offering (IPO) of 12.7 million shares of common stock at $24 per share, which includes the exercise in full by the underwriters of the offering of their option to purchase 1.7 million shares. Read More

Appointments & advancements

Agilis Biotherapeutics LLC, of New York, named Greg Robinson chief scientific officer. Read More

In the clinic

Kinex Pharmaceuticals Inc., of Buffalo, N.Y., said the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute. KX2-361 (KX02), a dual src/pre-tubulin inhibitor, is a small molecule drug that has shown potent inhibitory activity against a broad panel of brain tumor cell lines, including those that are resistant to Temozolomide (T98G), the most widely used chemotherapy for the treatment of malignant glioma. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe